Takeda Pharmaceutical (TAK) revenue
Takeda Pharmaceutical (TAK) reported revenue of ¥4.51T in fiscal 2026 (the year ended March 31, 2026). That is 1.7% lower than the ¥4.58T of fiscal 2025. Figures as of 18 Nov 2026, 09:39 UTC, from Yahoo Finance.
Key facts
- Revenue, fiscal 2026
- ¥4.51T
- Change on fiscal 2025
- −1.7%
- Highest on record
- ¥4.58Tfiscal 2025
- Lowest on record
- ¥4.03Tfiscal 2023
- Fiscal years on record
- 42023–2026
Figures as of . Statements from Yahoo Finance. Amounts are in JPY. Figures, not advice.
Takeda Pharmaceutical revenue, in more detail
Across the 4 fiscal years on record (2023–2026), the highest was ¥4.58T in fiscal 2025 and the lowest ¥4.03T in fiscal 2023.
Revenue by fiscal year
Takeda Pharmaceutical revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2026 | ¥4.51T | 1.7% down | |
| 2025 | ¥4.58T | 7.5% up | |
| 2024 | ¥4.26T | 5.9% up | |
| 2023 | ¥4.03T | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| Takeda Pharmaceutical TAK | ¥4.51T | 2026 |
| Cencora COR | $321.33B | 2025 |
| Boston Scientific BSX | $20.07B | 2025 |
| Cardinal Health CAH | $254.25B | 2026 |
| argenx ARGX | $4.15B | 2025 |
| Edwards Lifesciences EW | $6.07B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Takeda Pharmaceutical, figure by figure
- Takeda Pharmaceutical market cap
- Takeda Pharmaceutical earnings
- Takeda Pharmaceutical earnings per share (EPS)
- Takeda Pharmaceutical P/E ratio
- Takeda Pharmaceutical P/S ratio
- Takeda Pharmaceutical P/B ratio
- Takeda Pharmaceutical free cash flow
- Takeda Pharmaceutical operating margin
- Takeda Pharmaceutical dividend
- Takeda Pharmaceutical shares outstanding
- Takeda Pharmaceutical total debt
- Takeda Pharmaceutical cash on hand
- Takeda Pharmaceutical total assets
- Takeda Pharmaceutical return on equity (ROE)
- Takeda Pharmaceutical return on invested capital (ROIC)
Takeda Pharmaceutical (TAK) overview: price, valuation and scorecardAll health care companies by market value
Takeda Pharmaceutical revenue: questions and answers
What is Takeda Pharmaceutical's revenue?
Takeda Pharmaceutical (TAK) reported revenue of ¥4.51T in fiscal 2026 (the year ended March 31, 2026). That is 1.7% lower than the ¥4.58T of fiscal 2025.
What are the highest and lowest revenue figures on record for Takeda Pharmaceutical?
Across the 4 fiscal years on record (2023–2026), the highest was ¥4.58T in fiscal 2025 and the lowest ¥4.03T in fiscal 2023.
How is Takeda Pharmaceutical's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Takeda Pharmaceutical it is on record here for 4 fiscal years, 2023 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Takeda Pharmaceutical (TAK) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/TAK/revenue
Underlying data: Yahoo Finance.